The most valuable drug race in pharmaceutical history keeps accelerating. Eli Lilly reported mid-stage data this month for an experimental combination called EloraTZP, pairing its amylin-targeting drug eloralintide with tirzepatide, the active ingredient in Zepbound and Mounjaro. At 48 weeks, patients on the highest dose lost an average of 23.3 percent of their body weight, against 14.8 percent for tirzepatide alone. Blood sugar fell further too, with glycated haemoglobin down as much as 2.9 percent versus 2.4 percent on tirzepatide, EuropeSays reported.
On a cross-trial basis, 23.3 percent is competitive with anything Novo Nordisk has in the clinic. It beats Novo's CagriSema, which managed 15.7 percent at 68 weeks in a comparable population, and it sits within reach of Lilly's own retatrutide, which posted 28.3 percent at 80 weeks in the TRIUMPH-1 trial published in the New England Journal of Medicine last month, the highest pharmacological weight loss reported to date. The usual caveat applies. Cross-trial comparisons are not head-to-head results. But the direction is unmistakable, and it points one way.
Novo keeps losing the comparisons that matter
For Novo Nordisk, the EloraTZP data is the latest in a bruising sequence. CagriSema, the company's great hope for retaking the efficacy lead, missed non-inferiority against tirzepatide in the REDEFINE-4 trial, 20.2 percent versus 23.6 percent, and then missed again in a second head-to-head in August. Two misses against the incumbent is not a pipeline. It is a pattern. The FDA decision on CagriSema is expected in the fourth quarter, but the commercial question has already been answered by the data. Doctors prescribe the drug that works best, and right now that drug is Lilly's.
The scoreboard underneath tells the story. Zepbound did $4.93 billion in second-quarter sales, up 46 percent year over year, with weekly U.S. prescriptions roughly double those of injectable Wegovy. Novo's countermove has been the oral Wegovy pill, a once-daily 25 mg semaglutide tablet approved last December and launched in January. It has done real volume, more than 5 million U.S. prescriptions in seven months, capturing about 90 percent of oral obesity scripts, according to BioNixus's market tracker. But Lilly answered with orforglipron, the first non-peptide oral GLP-1, approved April 1 with no food or water restrictions, posting 11.2 percent weight loss at 72 weeks in the ATTAIN-1 trial. The pill battle is now a two-front war, and Lilly is winning the injectable war outright.
The amylin pivot
The deeper story is the industry's pivot beyond GLP-1s entirely. Amylin is a hormone released by the pancreas alongside insulin that regulates hunger, signals fullness, and slows stomach emptying. It acts through a distinct biological pathway from GLP-1, which means combining the two can push weight loss past what either achieves alone without simply escalating the dose of one drug. Both Lilly and Novo are betting the next wave of obesity medicine is multi-hormone, and the EloraTZP data is the first serious evidence the bet pays, as industry coverage this month detailed.
There is a catch, and it is not small. Discontinuation due to adverse events ran 10.8 to 27.0 percent on EloraTZP against 2.9 percent for tirzepatide alone, concentrated during dose escalation. More efficacy, more side effects. That is the oldest trade in pharmacology, and it is why Lilly plans an optimized titration schedule for the Phase III program it expects to start by the end of 2026. The larger trials will determine whether the weight loss replicates with tolerability patients can live with. Until then, 23.3 percent is a promise with an asterisk.
The price war nobody expected
Meanwhile the commercial ground is shifting under both companies. With the shortage era over, Lilly and Novo have launched direct-to-patient pharmacy programs at identical $499 monthly price points, NovoCare for Wegovy and LillyDirect's self-pay program for Zepbound vials. Cash-pay patients get branded drugs at a fixed price, a direct assault on the compounders that flourished during the shortage and a quiet admission that insurance coverage still does not match demand. As Lilly's Patrik Jonsson put it, every major medical organization recognizes obesity as a chronic disease, yet insurance and federal programs do not systematically cover it, The Educated Patient reported.
And then there is the strangest subplot. Both companies now claim their GLP-1 drugs slow biological aging, citing molecular aging clocks that showed patients aging two to three years more slowly than expected. Steve Horvath, the UCLA professor who invented the aging clock, called two years a pretty strong effect and said the data could support treating GLP-1s as geroprotectors, MIT Technology Review reported. Skepticism is warranted. These are company-funded readouts on company products, presented at a longevity conference, and slowing aging is a vastly bigger claim than shedding pounds. But if even a fraction of it replicates in independent trials, the addressable market for these drugs stops being the obese and becomes everyone. That is the kind of upside that makes a 23.3 percent weight loss readout move two of the largest drug stocks on earth. The third act of the obesity drug war is not about who loses the most weight. It is about who owns the next decade of medicine.
Topics health
